Johnson & Johnson reports Q3 2026 results on October 13, with MedTech segment performance under scrutiny after Q2 revenue of $8.93 billion rose just 4.5% year-over-year amid softer cardiovascular trends. Analysts project MedTech near $8.78 billion, reflecting headwinds from electrophysiology competition, Abiomed procedure selectivity following trial data, and China volume-based procurement pressures, partially offset by potential acceleration in surgery via OTTAVA robotic launch, vision, and orthopedics. Innovative Medicine strength supports overall company guidance of $100.8–101.4 billion in full-year sales, yet MedTech margins and volumes remain key swing factors for the quarter's outcome relative to consensus thresholds.